HM820 - Class 5 (Producers Decisions) Flashcards

1
Q

What is Dynamic Efficiency

A

Incentivizing pharmaceutical innovation - basically dangling a carrot in front of pharma that there are profits down the road.

Examples: Patents, grants, advanced market commitments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is static efficiency

A

Making sure there are low prices for patients today. Prices staying low.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is third-degree price discrimination:

A

different prices by GROUP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What would a pharmaceutical company prefer to develop: a treatment or a preventive?

A

Treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Can pharma companies price discriminate based on risk of contracting a disease?

A

No!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When can pharma companies price discriminate?

A

Setting different prices by purchaser (country or PBM).

But prices cannot vary by disease, indication, genetic risk, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Advanced Market Commitments

A

Agreement to purchase drugs ahead of time. A Dynamic Efficiency strategy

They are are an alternative to patents as a way to incentivize R&D.

Why are they needed? Michael Kremer describes a commitment problem: low-income countries cannot credibly commit to honoring certain patents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the goal for Patent Buyouts

A

Boost static efficiency without harming dynamic efficiency.

A Mechanism for Encouraging Innovation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are surrogate endpoints often used to accomplish in clinical trials

A

A way that FDA can facilitate faster drug approval for certain diseases?

A more immediate outcome in clinical trials. The FDA can sometimes approve drugs based not on mortality but on some surrogate endpoint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the Incremental Cost
Effectiveness equation

A

The difference in costs divided by the difference in effectiveness.

Ca - Cb / Ea - Eb = $ per QALY

The bottom is Qualy’s and the top is drug costs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why does the Kremer-Snyder model suggest that pharmaceutical companies prefer treatments over preventives? (Quiz Question)

Higher profit margins on preventives
Easier marketing strategies
Difficulty in price discrimination
Lower production costs
Faster FDA approval

A

Difficulty in price discrimination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

All else equal, which of the following R&D projects would probably be most profitable? (Quiz Question)

A vaccine that would save millions of lives in very low-income countries

A drug that would prevent cancer from occurring

A drug that would treat early-stage cancer

A new antibiotic

A drug that would extend the lives of those suffering from late-stage cancer and about to die.

A

A drug that would extend the lives of those suffering from late-stage cancer and about to die.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly